RU2007105822A - 5-[3-(4-бензилоксифенилтио)-фур-2-ил]-имидазолидин-2,4-дион и аналоги в качестве ингибиторов эластазы макрофагов - Google Patents
5-[3-(4-бензилоксифенилтио)-фур-2-ил]-имидазолидин-2,4-дион и аналоги в качестве ингибиторов эластазы макрофагов Download PDFInfo
- Publication number
- RU2007105822A RU2007105822A RU2007105822/04A RU2007105822A RU2007105822A RU 2007105822 A RU2007105822 A RU 2007105822A RU 2007105822/04 A RU2007105822/04 A RU 2007105822/04A RU 2007105822 A RU2007105822 A RU 2007105822A RU 2007105822 A RU2007105822 A RU 2007105822A
- Authority
- RU
- Russia
- Prior art keywords
- methoxyphenyl
- chlorophenyl
- methylphenyl
- benzyloxyphenylthio
- imidazolidin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (6)
1. Соединение формулы (IV) или его фармацевтически приемлемая соль
где R выбран из группы, состоящей из фенила, 4-бензилоксифенила, 4-дифенила, 4-метоксифенила, 3-метоксифенила, 2-метоксифенила, 3,5-диметоксифенила, 4-хлорфенила, 3-хлорфенила, 2-хлорфенила, 4-метилфенила, 3-метилфенила, 2-метилфенила и 3-трифторметилфенила.
2. Соединение по п.1, где R представляет собой 4-метоксифенил.
3. Фармацевтическая композиция, содержащая соединение формулы (IV) или его фармацевтически приемлемую соль
где R представляет собой замещенную группу, выбранную из группы, состоящей из фенила, 4-бензилоксифенила, 4-дифенила, 4-метоксифенила, 3-метоксифенила, 2-метоксифенила, 3,5-диметоксифенила, 4-хлорфенила, 3-хлорфенила, 2-хлорфенила, 4-метилфенила, 3-метилфенила, 2-метилфенила и 3-трифторметилфенила.
4. Композиция по п.3, где R представляет собой 4-метоксифенил.
5. Способ ингибирования эластазы макрофагов человека (ММР-12), включающий введение пациенту, нуждающемуся в этом, терапевтически эффективного количества соединения формулы (IV) или его фармацевтически приемлемой соли
где R представляет собой замещенную группу, выбранную из группы, состоящей из фенила, 4-бензилоксифенила, 4-дифенила, 4-метоксифенила, 3-метоксифенила, 2-метоксифенила, 3,5-диметоксифенила, 4-хлорфенила, 3-хлорфенила, 2-хлорфенила, 4-метилфенила, 3-метилфенила, 2-метилфенила и 3-трифторметилфенила.
6. Способ по п.5, где R представляет собой 4-метоксифенил.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60273604P | 2004-08-19 | 2004-08-19 | |
| US60/602,736 | 2004-08-19 | ||
| US60/602?736 | 2004-08-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2007105822A true RU2007105822A (ru) | 2008-09-27 |
| RU2391339C2 RU2391339C2 (ru) | 2010-06-10 |
Family
ID=35968136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007105822/04A RU2391339C2 (ru) | 2004-08-19 | 2005-08-17 | 5-[3-(4-бензилоксифенилтио)-фур-2-ил]-имидазолидин-2,4-дион и аналоги в качестве ингибиторов эластазы макрофагов |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7179831B2 (ru) |
| EP (1) | EP1789036B1 (ru) |
| JP (1) | JP5042833B2 (ru) |
| KR (1) | KR101197325B1 (ru) |
| CN (1) | CN101014338B (ru) |
| AT (1) | ATE508744T1 (ru) |
| AU (1) | AU2005277432B2 (ru) |
| BR (1) | BRPI0514470B8 (ru) |
| CA (1) | CA2577430C (ru) |
| DK (1) | DK1789036T3 (ru) |
| ES (1) | ES2364068T3 (ru) |
| HK (1) | HK1107774A1 (ru) |
| MX (1) | MX2007001940A (ru) |
| NZ (1) | NZ553258A (ru) |
| RU (1) | RU2391339C2 (ru) |
| SI (1) | SI1789036T1 (ru) |
| WO (1) | WO2006023562A2 (ru) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008051260A1 (en) * | 2006-01-13 | 2008-05-02 | Battelle Memorial Institute | Methods for assessing copd-retlated diseases |
| EP2907512A1 (en) | 2014-02-14 | 2015-08-19 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Inhibitors of MMP-12 as antiviral Agents |
| US10532102B2 (en) | 2016-08-19 | 2020-01-14 | Foresee Pharmaceuticals Co., Ltd. | Pharmaceutical composition and methods of uses |
| AU2017313897B2 (en) * | 2016-08-19 | 2020-06-18 | Foresee Pharmaceuticals Co., Ltd. | Pharmaceutical composition and methods of uses |
| EP3517531B1 (en) * | 2016-09-23 | 2021-02-24 | Kaken Pharmaceutical Co., Ltd. | Method for producing (r)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2h)-yl)methyl]imidazolidine-2,4-dione and intermediate for producing same |
| DK3793995T3 (da) * | 2018-05-15 | 2024-04-08 | Foresee Pharmaceuticals Usa Inc | Matrix metalloproteinase (MMP)-inhibitorer og fremgangsmåder til anvendelse deraf |
| US11673884B2 (en) | 2019-11-14 | 2023-06-13 | Foresee Pharmaceuticals Co., Inc. | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof |
| CN117545477A (zh) * | 2021-06-08 | 2024-02-09 | 逸达生物科技股份有限公司 | Mmp-12抑制剂的安全施用 |
| RU2766551C1 (ru) * | 2021-07-19 | 2022-03-15 | Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) | 5-(4-хлорфенил)-3-((4-хлорфенил)амино)-5-(фенилтио)фуран-2(5н)-он, обладающий противомикробной активностью |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6352976B1 (en) | 1998-12-31 | 2002-03-05 | Aventis Pharmaceuticals Inc. | Selective inhibitors of MMP-12 |
| AU1817700A (en) | 1998-12-31 | 2000-07-24 | Aventis Pharmaceuticals Inc. | 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12 |
| US6897237B2 (en) | 2000-04-28 | 2005-05-24 | Shionogi & Co. Ltd. | MMP-12 inhibitors |
| SE0100903D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| EP1397137B1 (en) | 2001-05-25 | 2009-10-14 | Bristol-Myers Squibb Company | Hydantion derivatives as inhibitors of matrix metalloproteinases |
| EP1394159A1 (fr) | 2002-08-13 | 2004-03-03 | Warner-Lambert Company LLC | Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
| SE0202539D0 (sv) | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
| GB0219896D0 (en) | 2002-08-27 | 2002-10-02 | Bayer Ag | Dihydropyridine derivatives |
| US7041693B2 (en) * | 2002-10-04 | 2006-05-09 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
-
2005
- 2005-08-17 SI SI200531283T patent/SI1789036T1/sl unknown
- 2005-08-17 KR KR1020077006294A patent/KR101197325B1/ko active IP Right Grant
- 2005-08-17 JP JP2007527975A patent/JP5042833B2/ja not_active Expired - Fee Related
- 2005-08-17 MX MX2007001940A patent/MX2007001940A/es active IP Right Grant
- 2005-08-17 CN CN2005800285556A patent/CN101014338B/zh not_active Expired - Fee Related
- 2005-08-17 US US11/205,954 patent/US7179831B2/en active Active
- 2005-08-17 CA CA2577430A patent/CA2577430C/en not_active Expired - Fee Related
- 2005-08-17 DK DK05786673.3T patent/DK1789036T3/da active
- 2005-08-17 AT AT05786673T patent/ATE508744T1/de not_active IP Right Cessation
- 2005-08-17 RU RU2007105822/04A patent/RU2391339C2/ru not_active IP Right Cessation
- 2005-08-17 ES ES05786673T patent/ES2364068T3/es active Active
- 2005-08-17 BR BRPI0514470A patent/BRPI0514470B8/pt not_active IP Right Cessation
- 2005-08-17 EP EP05786673A patent/EP1789036B1/en not_active Not-in-force
- 2005-08-17 AU AU2005277432A patent/AU2005277432B2/en not_active Ceased
- 2005-08-17 WO PCT/US2005/029259 patent/WO2006023562A2/en active Application Filing
- 2005-08-17 NZ NZ553258A patent/NZ553258A/en not_active IP Right Cessation
-
2008
- 2008-02-11 HK HK08101512.9A patent/HK1107774A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| SI1789036T1 (sl) | 2011-09-30 |
| EP1789036A2 (en) | 2007-05-30 |
| WO2006023562A3 (en) | 2006-04-20 |
| US20060041000A1 (en) | 2006-02-23 |
| MX2007001940A (es) | 2007-07-24 |
| EP1789036B1 (en) | 2011-05-11 |
| KR101197325B1 (ko) | 2012-11-05 |
| DK1789036T3 (da) | 2011-06-27 |
| CN101014338B (zh) | 2010-06-16 |
| CA2577430A1 (en) | 2006-03-02 |
| JP2008510701A (ja) | 2008-04-10 |
| RU2391339C2 (ru) | 2010-06-10 |
| EP1789036A4 (en) | 2008-08-27 |
| KR20070045330A (ko) | 2007-05-02 |
| BRPI0514470B1 (pt) | 2021-01-05 |
| ES2364068T3 (es) | 2011-08-24 |
| CA2577430C (en) | 2010-12-07 |
| CN101014338A (zh) | 2007-08-08 |
| NZ553258A (en) | 2011-02-25 |
| JP5042833B2 (ja) | 2012-10-03 |
| US7179831B2 (en) | 2007-02-20 |
| HK1107774A1 (en) | 2008-04-18 |
| BRPI0514470A (pt) | 2008-06-10 |
| AU2005277432B2 (en) | 2011-11-24 |
| WO2006023562A2 (en) | 2006-03-02 |
| AU2005277432A1 (en) | 2006-03-02 |
| BRPI0514470B8 (pt) | 2021-07-20 |
| ATE508744T1 (de) | 2011-05-15 |
| WO2006023562B1 (en) | 2006-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007105822A (ru) | 5-[3-(4-бензилоксифенилтио)-фур-2-ил]-имидазолидин-2,4-дион и аналоги в качестве ингибиторов эластазы макрофагов | |
| LU92555I2 (fr) | Empagliflozine et ses sels, en particulier Empagliflozine (*) (*) l'ingrédient actif approuvé est l'Empagliflozine de formule (1S)-1,5anhydro-1-C-{4-chloro-3-¬(4-{¬(3S)-oxolan-3-yloxyl}phényl)méthylphényl}-D-glucitol | |
| JP2005536475A5 (ru) | ||
| RU2005108133A (ru) | Дипептиднитрильные ингибиторы катепсина к | |
| RU2011106374A (ru) | Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1 | |
| DK1487829T3 (da) | Thiadizolylpiperazinderivater, der er nyttige til behandling eller forebyggelse af smerte | |
| SE0301886D0 (sv) | New use V | |
| EA201001669A1 (ru) | Замещенные пиримидин-5-карбоксамиды 281 | |
| EP2103623A3 (en) | Novel macrocyclic inhibitors of Hepatitis C virus replication | |
| SE0301882D0 (sv) | New use I | |
| JP2007517543A5 (ru) | ||
| CA2478099A1 (en) | Inhibitors | |
| RS52601B (en) | BENZOTIAZEPINE DERIVATIVES AS A RYANODIN (RYR2) RECEPTOR INHIBITOR AND THEIR USE IN THE TREATMENT OF HEART DISEASES | |
| RU2014114120A (ru) | Производные бензойной кислоты в качестве ингибиторов эукариотического фактора инициации трансляции 4е | |
| RU2008129723A (ru) | Ингибиторы ccr9 активности | |
| RU2010141823A (ru) | Соединения и способ снижения мочевой кислоты | |
| RU2008138163A (ru) | 4-фенилтиазол-5-карбоновые кислоты и амиды 4-фенилтиазол-5-карбоновой кислоты как ингибиторы polo-подобной киназы plk1 | |
| EA200501075A1 (ru) | Лекарственное средство для профилактики и лечения артериосклероза и гипертензии | |
| DK2017276T3 (da) | Phenylcarboxamid-forbindelser til behandling af smerte | |
| DK2113502T3 (da) | Hydrazidforbindelser og anvendelse deraf i farmaceutiske sammensætninger til behandling af hjerte-karsygdomme | |
| RU99101081A (ru) | Режим введения ингибиторов н+, к+-атфазы | |
| JP2008510701A5 (ru) | ||
| DK1360178T3 (da) | Hidtil ukendte heterocykliske analoger af diphenylethylenforbindelser | |
| EP1949893A3 (en) | Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors | |
| RU2008114853A (ru) | Сульфонамидные производные |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20150728 |
|
| TK4A | Correction to the publication in the bulletin (patent) |
Free format text: AMENDMENT TO CHAPTER -PC4A- IN JOURNAL: 23-2015 FOR TAG: (73) |
|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20200818 |